Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer
Clinical trial NCT03480152 · TERMINATED
Trial details
- NCT number
- NCT03480152
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-18
- Primary completion
- 2019-06-25
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.